Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC +7.06%98 EV-to-EBITDA is 18.29 as of Aug. 09, 2026, which is 34% below its 10-year median of 27.65. GuruFocus rates CHIX:GMABC with a GF Score™ of 98/100 and a GF Value™ of kr2,118.75 (Fairly Valued). The stock has 5 warning signs investors should review. Among 401 Biotechnology companies, Genmab AS ranks worse than 59.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genmab AS's enterprise value is kr149,103 Mil.
Genmab AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr8,151 Mil. Therefore, Genmab AS's EV-to-EBITDA for today is 18.29.
The historical rank and industry rank for Genmab AS's EV-to-EBITDA or its related term are showing as below:
CHIX:GMABc'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.84 Med: 27.65 Max: 99.53
Current: 18.29
During the past 13 years, the highest EV-to-EBITDA of Genmab AS was 99.53. The lowest was 5.84. And the median was 27.65.
CHIX:GMABc's EV-to-EBITDA is ranked worse than 59.1% of 401
companies
in the Biotechnology industry
Industry Median: 13.12
vs CHIX:GMABc: 18.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genmab AS's share price for today is kr2046.00.
Genmab AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr81.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Genmab AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Genmab AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genmab AS's EV-to-EBITDA falls into.
Genmab AS's current Enterprise Value is kr149,103 Mil.
Genmab AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr8,151 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (CHIX:GMABC) has a EV-to-EBITDA of 18.29 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genmab AS. This is 34% below median its historical median of 27.65. Over the past decade, Genmab AS's EV-to-EBITDA has ranged from 5.84 to 99.53. According to the industry distribution chart, Genmab AS ranks #237 out of 401 companies in the Biotechnology industry, placing it in the top 59.1%.
Is Genmab AS's EV-to-EBITDA too high?
Genmab AS's current EV-to-EBITDA of 18.29 is 34% below median its 10-year median of 27.65. Over the past 10 years, this metric has ranged from a low of 5.84 to a high of 99.53. The Biotechnology industry median EV-to-EBITDA is 13.12. Genmab AS's value of 18.29 is 39.4% above this industry median. Based on the distribution chart, Genmab AS ranks #237 out of 401 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #237 out of 401 companies for EV-to-EBITDA. This places Genmab AS in the lower half of its industry. The industry median EV-to-EBITDA is 13.12. Genmab AS's value of 18.29 is 39.4% above this benchmark. Historically, Genmab AS's own EV-to-EBITDA has ranged from 5.84 to 99.53 over the past decade. While the company's 10-year median is 27.65 vs. the industry median of 13.12, Genmab AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.12, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current EV-to-EBITDA of 18.29 is 39.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genmab AS. For the Biotechnology industry, the median EV-to-EBITDA is 13.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current EV-to-EBITDA is 18.29, which is 34% below median its own 10-year median of 27.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,118.75, compared to a current price of kr2,046.00 — trading 3.4% below its estimated fair value. The current EV-to-EBITDA is 18.29, which is 34% below median its 10-year median of 27.65 and 39.4% above the Biotechnology industry median of 13.12. Genmab AS's overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current EV-to-EBITDA is 18.29 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr2,046.00 is trading 3.4% below its estimated GF Value™ of kr2,118.75.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
EV-to-EBITDA: 18.29 (34% below median its 10-year median of 27.65)
GF Value™: kr2,118.75 vs. price of kr2,046.00 (3.4% below fair value)
Industry Position: 39.4% above the Biotechnology median (#237 of 401)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
98GF Score
Get the complete analysis for CHIX:GMABC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
